Some investors look at Pfizer (NYSE: PFE) as a has-been. That’s understandable in some ways. Sales for the company’s once-formidable COVID-19 franchise have tanked. So have Pfizer’s overall revenue, profits, and share price. However, there’s an argument that Pfizer is more of a “will-be” than a has-been. Could the drugmaker even be a trillion-dollar stock […]
If a dividend stock is struggling and falling in value, that pushes its yield up. This happens because while you are getting the same dividend, it is now costing you less money to acquire it. As long as the dividend remains sustainable, buying a dividend stock on a dip in price or near a low […]
The stock market is at record levels these days, but one company that isn’t reflecting that optimism is Pfizer (NYSE: PFE). Shares of the pharma giant are down 28% over the past 12 months as investors grow concerned about its long-term growth prospects. The company is in the midst of a transition as it pivots […]
Two companies stand at the center of the obesity drug market right now. Novo Nordisk continues to rake in money from its weight-loss drug Wegovy (and from off-label usage of its type 2 diabetes drug Ozempic.) Eli Lilly is hot on Novo Nordisk’s heels with its new obesity drug Zepbound. Pfizer (NYSE: PFE) remains on […]
Pfizer Inc. (NYSE: PFE) shares closed slightly higher on Wednesday. The New York-based pharmaceutical giant recently said that the European Commission approved PREVNAR 20, a caccine to help protect infants and children against pneumococcal disease. On Jan. 30, Pfizer reported a surprise profit for the fourth quarter, with adjusted EPS of 10 cents versus a […]
By Suzanne McGee and Tatiana Bautzer (Reuters) – An error by S&P Dow Jones Indices may have contributed to volatility in shares of Morgan Stanley, Pfizer, PNC Financial Services Group and other stocks in recent days, traders said. At issue was a list of pending changes to the Dow Jones U.S. Dividend 100 Index that […]
Pfizer believes the answer to its sliding valuation lies in oncology. The company, which is coming off one of the worst years in its history, unveiled on Thursday a new business unit dedicated to cancer research. The division, created in the wake of Pfizer’s $43 billion buyout of Seagen last year, houses a sprawling portfolio […]
With Pfizer (NYSE: PFE) stock hovering near a five-year low, one analyst has just started coverage of the pharmaceutical giant and is telling investors it’s time to buy. In a report released last week, Guggenheim analyst Vamil Divan said he believes Pfizer is worth $36 per share. That would represent a gain of about 30% […]
Pfizer Inc. (NYSE:PFE) stock closed at $27.11 at the end of the trading session on February 14. The 52-week price range is $25.76 and $43.37, On January 30, the pharma giant released its earnings for the year ending December 31, 2023. During fiscal 2023, the company returned $9.2 billion to shareholders in the form of […]
By Mike Scarcella (Reuters) – Pfizer has agreed to pay $93 million to settle antitrust claims by wholesale drug distributors that accused it of conspiring with India’s Ranbaxy Laboratories to delay sales of less expensive, generic versions of the cholesterol drug Lipitor. Attorneys for Lipitor purchasers including Rochester Drug Co-Operative Inc and Puerto Rico’s Drogueria […]
Pfizer Inc. (NYSE:PFE) closed at $26.57 at the end of trading on Feb. 6. In the preceding 52 weeks, the stock price fluctuated between a low price of $25.76 to a high price of $44.33. On Jan. 30, the pharmaceutical and biotechnology company released its earnings for the year ending Dec. 31, 2023. During fiscal […]
Income-seeking investors usually don’t think of the innovation-dependent pharmaceutical industry as a place to look for businesses with reliable cash flows. Dividend seekers have a good reason to be cautious regarding drugmaker stocks. Profit driven by patent-protected market exclusivity can disappear in the blink of an eye after those patents expire. Image source: Getty Images. […]